Akiva P Novetsky1, Marla J Keller2, Ana Gradissimo3, Zigui Chen3, Stephanie L Morgan4, Xiaonan Xue5, Howard D Strickler5, José A Fernández-Romero6, Robert Burk7, Mark H Einstein8. 1. Department of Obstetrics and Gynecology & Women's Health, Montefiore Medical Center and Albert Einstein College of Medicine, 1695 Eastchester Road, Suite 601, Bronx, NY 10461, USA. Electronic address: anovetsk@montefiore.org. 2. Department of Medicine and Obstetrics & Gynecology and Women's Health, Montefiore Medical Center and Albert Einstein College of Medicine, 1300 Morris Park Avenue, Block, Room 512, Bronx, NY 10461, USA. 3. Department of Pediatrics, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann Building, Room 515, Bronx, NY 10461, USA. 4. Department of Obstetrics and Gynecology & Women's Health, Montefiore Medical Center and Albert Einstein College of Medicine, 1695 Eastchester Road, Suite 601, Bronx, NY 10461, USA. 5. Department of Epidemiology & Population Health, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Belfer Building, Room 1312A, Bronx, NY 10461, USA. 6. Population Council, Center for Biomedical Research, 1230 York Avenue, New York, NY 10065, USA; Science Department, Borough of Manhattan Community College, The City University of New York, New York, NY 10007, USA. 7. Department of Pediatrics, Microbiology & Immunology, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann Building, Room 515, Bronx, NY 10461, USA; Department of Epidemiology & Population Health, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann Building, Room 515, Bronx, NY 10461, USA; Department of Obstetrics, Gynecology & Women's Health, Albert Einstein College of Medicine, 1300 Morris Park Avenue, Ullmann Building, Room 515, Bronx, NY 10461, USA. 8. Department of Obstetrics and Gynecology & Women's Health, Montefiore Medical Center and Albert Einstein College of Medicine, 1695 Eastchester Road, Suite 601, Bronx, NY 10461, USA; Department of Obstetrics and Gynecology, Rutgers New Jersey Medical School, USA.
Abstract
OBJECTIVE: To assess in vitro efficacy of Divine 9, a carrageenan-based vaginal lubricant that is being studied as a microbicide to inhibit HPV16 pseudovirus (PsV) infection. METHODS: Sexually active US women between 19 and 35years without prior HPV vaccination or cervical intraepithelial neoplasia were instructed to use Divine 9 vaginally with an applicator either before sex only or before and after intercourse. Women who applied a single dose of gel returned for cervicovaginal lavage (CVL) collection 1, 4 or 8-12h after intercourse versus those who applied gel before and after intercourse returned 1, 4 or 8-12h after the second gel dose. Carrageenan concentrations were assessed using an ELISA assay and the inhibitory activity was assessed using a PsV-based neutralization assay against HPV16 infection. Carrageenan concentrations and the percentage of PsV16 inhibition were compared using the Wilcoxon rank sum test. RESULTS: Thirteen women were enrolled and thirty specimens from different time-points were assessed. 87% of CVL samples had detectable carrageenans with levels decreasing over time from intercourse. 93% of CVL samples had detectable PsV16 inhibition with median inhibition of 97.5%. PsV16 inhibition decreased over time, but remained high, with median inhibition of 98.1%, 97.4% and 83.4% at 1, 4 and 8-12h, respectively. Higher carrageenan concentrations were associated with higher levels of PsV16 inhibition (rho=0.69). CONCLUSIONS: This is the first report of a human study investigating in vitro HPV inhibition of a carrageenan-based vaginal lubricant with CVL collected after sexual intercourse. We demonstrate excellent efficacy in preventing PsV16 infection.
OBJECTIVE: To assess in vitro efficacy of Divine 9, a carrageenan-based vaginal lubricant that is being studied as a microbicide to inhibit HPV16 pseudovirus (PsV) infection. METHODS: Sexually active US women between 19 and 35years without prior HPV vaccination or cervical intraepithelial neoplasia were instructed to use Divine 9 vaginally with an applicator either before sex only or before and after intercourse. Women who applied a single dose of gel returned for cervicovaginal lavage (CVL) collection 1, 4 or 8-12h after intercourse versus those who applied gel before and after intercourse returned 1, 4 or 8-12h after the second gel dose. Carrageenan concentrations were assessed using an ELISA assay and the inhibitory activity was assessed using a PsV-based neutralization assay against HPV16 infection. Carrageenan concentrations and the percentage of PsV16 inhibition were compared using the Wilcoxon rank sum test. RESULTS: Thirteen women were enrolled and thirty specimens from different time-points were assessed. 87% of CVL samples had detectable carrageenans with levels decreasing over time from intercourse. 93% of CVL samples had detectable PsV16 inhibition with median inhibition of 97.5%. PsV16 inhibition decreased over time, but remained high, with median inhibition of 98.1%, 97.4% and 83.4% at 1, 4 and 8-12h, respectively. Higher carrageenan concentrations were associated with higher levels of PsV16 inhibition (rho=0.69). CONCLUSIONS: This is the first report of a human study investigating in vitro HPV inhibition of a carrageenan-based vaginal lubricant with CVL collected after sexual intercourse. We demonstrate excellent efficacy in preventing PsV16 infection.
Authors: Jeffrey N Roberts; Rhonda C Kines; Hormuzd A Katki; Douglas R Lowy; John T Schiller Journal: J Natl Cancer Inst Date: 2011-04-11 Impact factor: 13.506
Authors: Aixa Rodríguez; Kyle Kleinbeck; Olga Mizenina; Larisa Kizima; Keith Levendosky; Ninochka Jean-Pierre; Guillermo Villegas; Brian E Ford; Michael L Cooney; Natalia Teleshova; Melissa Robbiani; Betsy C Herold; Thomas Zydowsky; José A Fernández Romero Journal: Antiviral Res Date: 2014-06-05 Impact factor: 5.970
Authors: Peter H Kilmarx; Kelly Blanchard; Supaporn Chaikummao; Barbara A Friedland; Nucharee Srivirojana; Cathy Connolly; Paisit Witwatwongwana; Somsak Supawitkul; Philip A Mock; Thanyanan Chaowanachan; Jordan Tappero Journal: Sex Transm Dis Date: 2008-03 Impact factor: 2.830
Authors: Janneke H H M van de Wijgert; Sarah L Braunstein; Neetha S Morar; Heidi E Jones; Lorna Madurai; Tammy T Evans Strickfaden; Manivasan Moodley; Jamila Aboobaker; Gugulethu Ndlovu; Taja M Ferguson; Barbara A Friedland; Clyde E Hart; Gita Ramjee Journal: J Acquir Immune Defic Syndr Date: 2007-12-15 Impact factor: 3.731
Authors: Jeffrey N Roberts; Christopher B Buck; Cynthia D Thompson; Rhonda Kines; Marcelino Bernardo; Peter L Choyke; Douglas R Lowy; John T Schiller Journal: Nat Med Date: 2007-07-01 Impact factor: 53.440
Authors: S Magnan; J E Tota; M El-Zein; A N Burchell; J T Schiller; A Ferenczy; P-P Tellier; F Coutlée; E L Franco Journal: Clin Microbiol Infect Date: 2018-04-21 Impact factor: 8.067
Authors: Nina Derby; Meropi Aravantinou; Jessica Kenney; Shweta R Ugaonkar; Asa Wesenberg; Jolanta Wilk; Larisa Kizima; Aixa Rodriguez; Shimin Zhang; Olga Mizenina; Keith Levendosky; Michael L Cooney; Samantha Seidor; Agegnehu Gettie; Brooke Grasperge; James Blanchard; Michael Piatak; Jeffrey D Lifson; José Fernández-Romero; Thomas M Zydowsky; Melissa Robbiani Journal: Drug Deliv Transl Res Date: 2017-12 Impact factor: 4.617
Authors: Tomasz Osmałek; Anna Froelich; Barbara Jadach; Adam Tatarek; Piotr Gadziński; Aleksandra Falana; Kinga Gralińska; Michał Ekert; Vinam Puri; Joanna Wrotyńska-Barczyńska; Bozena Michniak-Kohn Journal: Pharmaceutics Date: 2021-06-15 Impact factor: 6.321
Authors: Nina Derby; Manjari Lal; Meropi Aravantinou; Larisa Kizima; Patrick Barnable; Aixa Rodriguez; Manshun Lai; Asa Wesenberg; Shweta Ugaonkar; Keith Levendosky; Olga Mizenina; Kyle Kleinbeck; Jeffrey D Lifson; M Melissa Peet; Zachary Lloyd; Michael Benson; Walid Heneine; Barry R O'Keefe; Melissa Robbiani; Elena Martinelli; Brooke Grasperge; James Blanchard; Agegnehu Gettie; Natalia Teleshova; José A Fernández-Romero; Thomas M Zydowsky Journal: Nat Commun Date: 2018-09-24 Impact factor: 14.919